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INTRODUCTION 
Tuberculosis caused by bacteria Mycobacterium tuberculosis complex is one of 
the oldest diseases and still a major cause of death worldwide. The disease 
usually affects lungs, but other organs including eye can be affected. Ocular 
tuberculosis is one of the most important causes for Uveitis.  Ocular 
tuberculosis can be primary, where the eye is the initial port of entry, or 
secondary, where the organisms spread to the eye hematogenously.  When 
properly treated, tuberculosis caused by drug-susceptible strains of bacteria is 
curable in almost all cases.  
Tuberculosis remains a major health problem. In 2012WHO report 
stated “an estimated 8.6 million people developed TB and 1.3 million died 
from the disease. India and China alone accounted for 26% and 12% of global 
cases respectively”.2 
Close to 80% of tuberculosis occurs in the lungs , but ocular TB is one 
of the most important extra pulmonary manifestations3. Intraocular tuberculosis 
can happen without clinical activity in other parts of body and may resemble  
several clinical entities4 .Uveitis is the most common manifestation of 
intraocular TB and the most common clinical presentation appears to be 
 
 
posterior uveitis , followed by anterior uveitis,  panuveitis , and intermediate 
uveitis.5 
By definition uveitis implies inflammation of iris, ciliary body and 
choroid.6. There is no well defined criteria for diagnosis of intraocular TB 5,8. 
Chest x-ray, mantoux test, sputum microscopy and culture, PCR technique , 
quantiferon TB gold technique (IGRA)9  positron emission topography 10 , 
serum antipurified cord factor antibodies 11 and histo-pathological studies are 
available diagnostic modalities with their own limitations. However with the 
help of different modalities, better visual and systemic outcomes can be 
expected. In our study we will be following the guidelines given by Gupta et 
al.3,5 
For the inflammation associated with ocular TB treatment is given to 
treat both infection and inflammation.12,13 
Simultaneous infection by HIV greatly increases the risk of developing 
active tuberculosis and concomitant treatment with ART and ATT 14 can result 
in immune reconstitution inflammatory syndrome (IRIS)15,16 which makes the 
situation more difficult. 
 
 
 
 
 
EPIDEMIOLOGY 
Control of Tuberculosis in India is a big challenge. The burden of 
tuberculosis in India was always high and is still on rise. Every year, 1.8 
million persons develop the disease, of which about 800,000 are infectious; 
and, until recently, 370,000 died of it annually -1,000 every day. The disease is 
a serious barrier economic and social barrier. An estimate of 100 million 
workdays is lost due to illness. Society and the country also incur a huge cost 
due to TB-nearly US$ 3 billion in indirect costs and US$ 300 million in direct 
costs.16,17,18 
  
 
 
MYCOBACTERIUM TUBERCULOSIS 
Tubercle bacillus or Koch’s bacillus (named after discovery of the 
organism by Robert Koch in 1882) called Mycobacterium tuberculosis causes 
tuberculosis in the lungs and other tissues of the human body. The organism is 
a strict aerobe and thrives best in tissues with high oxygen tension such as in 
the apex of the lung. Out of various pathogenic strains for human disease 
included in Mycobacterium tuberculosis complex, currently most common is 
M. tuberculosis hominis (human strain), while M. tuberculosis bovis (bovine 
strain) used to be common pathogen to human beings during the era of 
consumption of unpasteurised milk but presently constitutes a small number of 
human cases. Other less common strains included in the complex are M. 
africanum (isolated from patients from parts of Africa), M. microti, M. 
pinnipedii and M. canettii. A nonpathogenic strain, M. smegmatis, is found in 
the smegma and as contaminant in the urine of both men and women. 
M. tuberculosis hominis is a slender rod-like bacillus, 0.5 μm by 3 μm, is 
neutral on Gram staining, and can be demonstrated by the following methods: 
1. Acid fast (Ziehl-Neelsen) staining. The acid fastness of the tubercle bacilli is 
due to mycolic acids, cross-linked fatty acids and other lipids in the cell wall of 
the organism making it impermeable to the usual stains. It takes up stain by 
 
 
heated carbol fuchsin and resists decolourisation by acids and alcohols (acid 
fast and alcohol fast) and can be decolourised by 20% sulphuric acid 
(compared to 5% sulphuric acid for declourisation for M. leprae which are less 
acid fast)  
1. False positive AFB staining is seen due to Nocardia, Rhodococcus, 
Legionella, and some protozoa such as Isospora and Cryptosporidium. 
2. Fluorescent dye methods. 
3. Culture of the organism from sputum in Lowenstein- Jensen (L.J.) 
medium for 6 weeks. 
4. Guinea pig inoculation method by subcutaneous injection of the 
organisms. 
5. Molecular methods such as PCR are the most recent methods. 
 
HIV-ASSOCIATED TUBERCULOSIS:  
HIV-infected individuals have very high incidence of tuberculosis all 
over the world. Vice-versa, rate of HIV infection in patients of tuberculosis is 
very high. Moreover, HIV-infected individual on acquiring infection with 
tubercle bacilli develops active disease rapidly (within few weeks) rather than 
after months or years. Pulmonary tuberculosis in HIV presents in typical 
manner. However, it is more often sputum smear negative but often culture 
 
 
positive. Extra-pulmonary tuberculosis is more common in HIV disease and 
manifests commonly by involving lymph nodes, pleura, pericardium, and 
tuberculous meningitis. Infection with M. avium-intracellulare (avian or bird 
strain) is common in patients with HIV/AIDS. 
  
 
 
MODES OF TRANSMISSION 
 Human beings acquire infection with tubercle bacilli by one of the 
following routes: 
 
 
 
 
 
 
INHALATION INGESTION INOCULATION TRANSPLACENTAL 
Via fresh 
infective 
droplets or dried 
sputum 
Via self 
swallowing of 
infective 
sputum or 
consuming 
milk infected 
with bovine TB 
bacilli 
Via inoculation 
of organism in to 
skin 
Congenital 
tuberculosis , spread 
from infected mother 
to foetus; very rare 
 
 
 
SPREAD OF TUBERCULOSIS 
 The disease spreads in the body by various routes: 
                                   VARIOUS WAYS OF SPREAD 
 
 
 
Local spread        lymphatic spread     haematogenous            via natural 
passages 
    By                       to lymphoid              spread                             
1.transbronchial  
Macrophages to       follicles                      by                                      spread 
Surrounding             in various            tuberculous bacillaemia     2.spread to                               
 Tissues.                  Parts of body                                                       peritone al                               
                                                                                                       Cavity from  
                                                                                                         Salphingitis  
etc; 
 
 
 
 
Tuberculin (Mantoux) skin test: 
 This test is done by intradermal injection of 0.1 ml of tuberculoprotein, 
purified protein derivative (PPD). Delayed type of hypersensitivity develops in 
individuals who are having or have been previously infected with tuberculous 
infection which is identified as an indurated area of more than 15 mm in 72 
hours. However, patients having disseminated tuberculosis may show negative 
test due to release of large amount of tuberculoproteins from the endogenous 
lesions masking the hypersensitivity test. A positive test is indicative of 
cellmediated hypersensitivity to tubercular antigens but does not distinguish 
between infection and disease. The test may be false positive in atypical 
mycobacterial infection and false negative in sarcoidosis, some viral infections, 
Hodgkin’s disease and fulminant tuberculosis. 
Immunisation against tuberculosis: 
 Protective immunization against tuberculosis is induced by injection of 
attenuated strains of bovine type of tubercle bacilli, Bacille Calmette-Guérin 
(BCG). Cell-mediated immunity with consequent delayed hypersensitivity 
reaction develops with healing of the lesion, but the cell-mediated immunity 
persists, rendering the host tuberculin-positive and hence immune. 
 
 
 
 
EVOLUTION OF TUBERCLE 
 The sequence of events which take place when tubercle bacilli are 
introduced into the tissue are as under: 
1. When the tubercle bacilli are injected intravenously in to the guinea pig, 
the bacilli are lodged in pulmonary capillaries where an initial response 
of neutrophils is evoked which are rapidly destroyed by the organisms. 
2. After about 12 hours, there is progressive infiltration by macrophages. 
This is due to coating of tubercle bacilli with  serum complement factors 
C2a and C3b which act as opsonins and attract the macrophages. 
Macrophages dominate the picture throughout the remaining life of the  
lesions. If the tubercle bacilli are, however, inhaled into the  lung alveoli, 
macrophages predominate the picture from the beginning. 
3. The macrophages start phagocytosing the tubercle bacilli and either kill 
the bacteria or die away themselves. In the latter case, they further 
proliferate locally as well as there is increased recruitment of 
macrophages from blood monocytes. 
4. As a part of body’s immune response, T and B cells are activated. 
Activated CD4+T cells develop the cell-mediated delayed type 
hypersensitivity reaction, while B cells result in formation of antibodies 
which play no role in body’s defence against tubercle bacilli. 
 
 
5. In 2-3 days, the macrophages undergo structural changes as a result of 
immune mechanisms-the cytoplasm becomes pale and eosinophilic and 
their nuclei become elongated and vesicular. These modified 
macrophages resemble epithelial cells and are called epithelioid cells. 
6. The epithelioid cells in time aggregate into tight clusters or granulomas. 
Release of cytokines in response to sensitized CD4+T cells and some 
constituents of mycobacterial cell wall play a role in formation of 
granuloma. 
7. Some of the macrophages form multinucleated giant cells by fusion of 
adjacent cells. The giant cells may be Langhans’  type having 
peripherally arranged nuclei in the form of horseshoe or ring, or 
clustered at the two poles of the giant cell; or they may be foreign body 
type having centrally-placed nuclei. 
8. Around the mass of epithelioid cells and giant cells is a zone of 
lymphocytes, plasma cells and fibroblasts. The lesion at this stage is 
called hard tubercle due to absence of central necrosis. 
9. Within 10-14 days, the centre of the cellular mass begins to undergo 
caseation necrosis, characterised by cheesy appearance and high lipid 
content. This stage is called soft tubercle which is the hallmark of 
tuberculous lesions.    
 
 
The development of caseation necrosis is possibly due to interaction of 
mycobacteria with activated T cells (CD4+ helper T cells via IFN-γ and 
CD8+ suppressor T cells directly) as well as by direct toxicity of 
mycobacteria on macrophages. 
Microscopically, caseation necrosis is structureless, eosinophilic and 
granular material with nuclear debris. 
10. The soft tubercle which is a fully-developed granuloma with caseous centre 
does not favour rapid proliferation of tubercle bacilli. Acid-fast bacilli are 
difficult to find in these lesions and may be demonstrated at the margins of 
recent necrotic foci and in the walls of the cavities. 
 
 
 
 
 
 
 
THE FATE OF A GRANULOMA IS VARIABLE: 
1. The caseous material may undergo liquefaction and extend into surrounding 
soft tissues, discharging the contents on the surface. This is called cold 
abscess although there are no pus cells in it. 
2. In tuberculosis of tissues like bones, joints, lymph nodes and epididymis, 
sinuses are formed and the sinus tracts are lined by tuberculous granulation 
tissue. 
3. The adjacent granulomas may coalesce together enlarging the lesion which 
is surrounded by progressive fibrosis. 
4. In the granuloma enclosed by fibrous tissue, calcium salts may get 
deposited in the caseous material (dystrophic calcification) and sometimes 
the lesion may even get ossified over the years. 
 
 
 
CLINICAL FEATURES OF INTRA OCULAR 
TUBERCULOSIS 
Any ocular tissue may be affected, including the ocular adnexa, the 
cornea, the sclera, the Uveal tract, the retina, and the optic nerve. 11Of the 
various manifestations of ocular TB, the most common clinical presentation 
appears to be  posterior Uveitis, followed by anterior Uveitis, pan Uveitis, and 
intermediate Uveitis. 
The clinical features of any Uveitic eye are described by the criteria given by 
SUN working group. 
“TABLE 1- SUN Working group Anatomical Classification Of Uveitis 
Type  Primary  site of 
inflammation 
includes 
Anterior Uveitis  Anterior  chamber Iritis, iridocyclitis, anterior cyclitis 
Intermediate  
Uveitis  
vitreous Pars planitis, posterior cyclitis, and 
hyalitis 
Posterior   Uveitis  Retina  or choroid focal or multifocal or diffuse 
choroiditis, chorioretintis , 
retinochoroiditis, retinitis and 
neuroretinitis 
Pan Uveitis  Anterior chamber, 
vitreous, retina and 
choroid” 
 
 
 
The clinical features of intraocular tuberculosis is well described by 
gupta et al.5 
“Table 2 – clinical presentation of intraocular tuberculosis 
1 Anterior uveitis Granulomatous,  
 non granulomatous 
iris nodules 
ciliary body tuberculoma 
2 Intermediate uveitis Granulomatous 
Non granulomatous 
With organizing exudates in pars 
plana/peripheral uvea 
3 Posterior and panuveitis Choroid tubercle 
Choroid tuberculoma 
Subretinal abscess 
Serpiginous like choroidtis 
4 Retinitis and retinal 
vasculitis 
 
5 Neuroretinitis and optic 
neuropathy 
 
6 Endophthalmitis and 
panophthalmitis” 
 
 
 
 
1. ANTERIOR UVEITIS 
Tuberculosis can cause acute or chronic granulomatous anterior Uveitis 
which may present with iris or angle granulomas with mutton-fat keratic 
precipitates and posterior synechiae. There may be mild or moderate recurrent 
iridocyclitis along with complicated cataract and possibly vitritis. 5 
 
The clinical features of anterior Uveitis is described by  the criteria given 
by SUN working group.21 
 
 
 
 
“TABLE 3- SUN working group grading scheme for anterior chamber 
cells 
GRADE CELLS/FIELD 
0 <1 
0.5 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
Field size is 1mm by 1mm slit beam” 
“TABLE 4- SUN working group grading scheme for anterior chamber 
flare 
GRADE DESCRIPTION 
0 none 
1+ faint 
2+ Moderate (iris and lens details clear) 
3+ Marked (iris and lens details hazy) 
4+ Intense (fibrinous or plastic aqueous) 
Field size is 1mm by 1mm slit beam” 
 
 
 
Mutton fat granulomatous KPs 
2. Intermediate Uveitis 
The common manifestation of intermediate Uveitis in intraocular 
tuberculosis is pars planitis. Patients generally present with following: 
· with a low– grade smoldering  chronic Uveitis 
·  vitritis 
·  snow ball opacities 
·  snow banking   
·  vascular sheathing in periphery 
·  retinochoroidal granuloma.5 
 
 
 
Snow ball opacities 
The grading of vitritis can be done according to the recommendations 
given by the ‘National Eye Institute system’ for grading vitreous haze. 
“Table 5 Grading of Vitreous Haze through the binocular indirect 
ophthalmoscope (BIO SCORE) 
SCORE DESCRIPTION CLINICAL FINDING 
0 nil none 
0.5 trace Occasional cells 
1 minimal Posterior pole clearly visible 
2 mild Posterior pole details slightly haze 
3 moderate Posterior pole details very haze 
4 marked Posterior pole details barely visible 
5 severe Fundus details not visible” 
 
 
3. POSTERIOR AND PAN UVEITIS 
             In tuberculous posterior Uveitis, the ocular manifestations include : 
1. Choroidal tubercles 
2. Choroidal tuberculoma 
3. Subretinal abscess and 
4. Serpiginous like choroiditis 
a. Choroidal Tubercles 
Most common intraocular manifestation of tubercular posterior Uveitis 
is multiple choroid tubercles .It occurs from hematogenous spread of the 
tubercular bacilli. Tuberculoma results occasionally from a tubercle that may 
continue to grow in to a solitary mass.  
 
 
 
            Picture showing choroidal lesion along superotemporal arcade and 
healed chorioretinal scars inferiorly. 
b. Choroidal Tuberculoma 
 Intraocular tuberculosis may present as a large tuberculoma. 5 
Various locations of  tuberculoma - anywhere in the choroid, in the 
macula, the equator, posterior pole or in a juxtapapillary location. 
The tuberculomas generally present  as a large solitary mass and may 
mimic a tumor. 
 
 
 
c. Subretinal abscess   
Multiplication of the bacilli in the granulomas  
 
 Liquefaction necrosis and abscess formation. 
 Gupta v et al has reported “these abscesses are more yellowish in color 
indicating liquefaction necrosis , have overlying retinal hemorrhages and have 
a tendency to develop retinal angiomatous  proliferation over a period of time. 
These lesions usually heal with ATT and healed lesions may show 
pigmentation and atrophy with chances of good visual recovery”.5 
 
 
 
d. Serpiginous-like choroidtis 
Serpiginous choroiditis  or otherwise known as geographic helicoids 
peripapillary choroidopathy is defined as “ a chronic ,recurrent inflammation 
that primarily involves the choroid and choriocapillaries and progresses to 
involve the retina secondarily”.5  A relentless progression  is common in 
tuberculous serpiginous like choroiditis lesions . 
4. Retnitis and Retinal vasculitis 
Patients with ocular tuberculosis can have vasculitis that may involve 
veins or rarely the arteries, and there may be associated systemic disease. 5 
verhoff and simpson reported “a tubercle within the central retinal vein in an 
eye enucleated for neovascular glaucoma” .  knox stated “periphlebitis was a 
common presentation of intra ocular tuberculosis , second only to chronic 
iridocyclitis.5whether the vasculitis per se is infective or whether it represents a 
hypersensitivity response to M.tuberculosis remains speculative”. 
                                       
 
 
 
 
 Organism in ocular tissue 
 
                                  Immune hypersensitivity response 
 
                                               vasculitis 
  
b. Eales Disease  
There are recent reports suggesting association of  tuberculosis with 
Eales disease due to demonstration of TB bacilli in vitreous samples from 
patients with Eales disease. 
 
 
Eales disease is usually peripheral, invariably bilateral retinal vasculitis 
resulting in peripheral non-perfusion and neovascularization in young male 
population. Patients present with painless vision loss of varying degrees, 
usually due to vitreous hemorrhage, and rarely due to retinal ischemia . 
The various stages of  Eales disease are: 
1. Stage of inflammation 
2. Stage of ischemia 
3. Stage of neovascularization 
4. Stage of  sequelae 
5. Neuroretinitis and Optic neuropathy 
Tuberculous optic neuropathy is  either due to - direct infection or  a 
hypersensitivity reaction to tuberculous bacilli.22 The involvement of the nerve 
may manifest as an optic nerve tubercle , papillitis , papilledema , optic 
neuritis, retrobulbar neuritis, neuroretinits , or optic chiasmatic arachnoiditis. 5 
6. Endophthalmitis and Panophthalmitis   
 
 
 
 
INVESTIGATIONS FOR OCULAR TUBERCULOSIS 
1. Ocular imaging studies in intraocular tuberculosis 
1. Fluroscein angiography 
      On angiography in case of choroidal tubercles there is hypofluorescence 
during dye transit followed by hyperfluorescence in later stages. Inactive 
lesions may show hyperfluorescence during dye transmission.  large choroidal 
granulomas show early hyperfluorescence  and pooling of dye during the late 
phase.  
In diffuse serpiginous like choroiditis - fluorescein  angiography shows 
an initial hypofluorescent active edge  and diffuse staining of the active 
advancing edge.5 
 
 
 
 
A. Choroidal tubercle near macula 
B. Fundus fluoresecein angiography showing -  vascular staining and 
perivascular leakage over the lesion suggesting active retinitis 
C. Fundus fluorescein angiography showing -  well demarcated choroidal 
tubercle with hyper fluorescence and pooling of dye.  
2 .Indocyanine green angiography  
      Subclinical choroidal lesions can be detected in Indocyanine green 
angiography which are seen as early & intermediate hypofluorescent spots  and  
iso or hyperfluorescent during the late phases . Since ICG changes are 
reversible , they can be used to monitor response to theraphy. 5 
3. Optical coherence tomography: 
  With  a relatively clear media, OCT can help detect retinal pathologies 
such as subretinal neovascular membrane and CME.  
4.Ultrasonography  
       Ultrasonography is useful for differentiating retinoblastoma , malignant 
melanoma & metastatic tumors from tuberculomas. 
 
 
 
5.Ultrasound Biomicroscopy 
UBM is used to detect granuloma in the parsplana region. 
2. Systemic investigations    
1. Purified Protein Derivative /Mantoux skin test and Its Interpretation: 
· done because ocular hypersensitivity is related to cutaneous 
hypersensitivity 
· done by giving intradermal injection of 5 TU of purified protein 
derivative to raise a wheal of 6- 10 mm. 
· result is read by measuring induration at the site of injection at 48-72 
hrs. 
INDURATION 
MEASUREMENT 
RESULT SPECIAL CONSIDERATION 
Less than 5 mm negative nil 
5- 10 mm positive If patient is HIV positive or if 
patient Has healed tuberculous 
lesions In chest radiograph 
More than 10 mm positive If patient resides in high 
incidence areas or patient lives in 
high risk settings 
15 mm positive  
 
 
 
FALSE NEGATIVE: 
1. Severe tuberculous infection 
2. Moribund patient 
FALSE POSITIVE: 
Vaccination with BCG 
2. Chest Radiography and Computerized Tomography 
Active or healed /primary or reactivated  pulmonary tuberculosis can be 
made out with chest radiograph. chest x-ray can provide evidence of 
tuberculosis.  Unilateral or bilateral Hilar or paratracheal lymph node 
enlargement is quite characteristic of primary tuberculosis. Inactive disease is 
characterized by Calcified hilar lymph nodes or pulmonary nodules . 
Computerized tomography of the chest and skeleton and cerebral MRI are 
more sensitive than radiograph. 
3.Serodiagnosis 
Serodiagnostics tests have low sensitivity and high false positive rates & 
hence not preferred currently. 
 
 
4. Interferon–g release assays(IGRA) 
This test measures interferon-gamma released by sensitized T cells after 
stimulation by M.tuberculosis antigens.5The newer versions of the test use 
antigens that are very specific to M.tuberculosis  and include -  early secreted 
antigen test (ESAT) 6, culture filtrate protein (CFP)-10. The newer antigens are 
more specific are not shared with BCG vaccine strains or other species of 
Mycobacterium .Two kits are available commercially –  
1. T-SPOT.TB test (Oxford immunotec Ltd,Oxford,UK)   
2. Quantiferon – TB GOLD (Carnegie,Australia). 
Doycheva D et al concluded that “ In quantiferon positive patients with 
severe Uveitis  forms such as serpiginous choroiditis and occlusive retinal 
vasculitis, 18 F-FDG-PET/CT 18(F-fluorodeoxyglucose positron emission 
tomography /CT) is useful to identify lesions appropriate for biopsy and helps 
to establish the diagnosis and appropriate therapy for presumed tuberculosis-
induced intraocular inflammation”.10 
Ang m et al  in a prospective cohort study stated that “ the interferon 
gamma release assay (IFN-c)(IGRAs) can be used as diagnostic test for 
 
 
tuberculosis (TB)-associated Uveitis in  combination with clinical signs and 
TST to diagnose TAU”.9  
5.Xpert MTB/RIF(a new rapid molecular test) 
WHO TB report 2013 Xpert MTB/RIF states that, “ a rapid molecular 
diagnostic test , is being rapidly adopted by countries to detect TB and 
rifampicin –resistant TB. By end of june 2013,1402 testing machines and 3.2 
million test cartridges had been procured by 88 of the 145 countries eligible for 
concessional prices”. 
3.Direct evidence from ocular tissues: 
1. Examination of smear and staining for Acid-Fast organisms  
Direct microscopy of the smears is not often helpful in the diagnosis of 
intraocular tuberculosis since the yield of organisms from intraocular fluids is 
low. In  cases with ceseation necrosis and endophthalmitis which might yield 
more bacilli, examinations of stained smears from these eyes may help 
establish the diagnosis. 
 
 
 
 
2.Culture of intraocular fluid/tissue: 
Culture media:   Lowenstein –Jensen medium 
Duration :  8 weeks 
Staining :   ziehl-neelson stain 
Drawbacks: . 
1. The process is prolonged and cumbersome 
2. May not provide positive results because of the low yield of organisms 
from the intraocular fluids. 
3.Polymerase Chain Reaction: 
        This is especially useful for intraocular fluids, because PCR can amplify  
mycobacterial DNA several –fold for easy detection and hence can be 
performed with very small sample sizes. Samples can be - aqueous ,vitreous 
humor, subretinal  fluid, or rarely, tissue obtained by chorioretinal biopsy. 5The 
reported PCR-positivity for M.tuberculosis is 33% of cases in retinal vasculitis 
and 66% in granulomatous panuveitis. Wroblewosky at al in a restropective 
case series  suggested that in dealing with those populations  at increased risk 
 
 
of tuberculosis or patients receiving biologic therapy ,these tests are 
recommended. 
  
 
 
DIAGNOSIS OF INTRAOCULAR TUBERCULOSIS 
       There is no well defined criteria for diagnosis of intraocular tuberculosis. 
Based on clinical parameters , follow-up examinations, Therapeutic response to 
ATT and laboratory investigations like PCR analysis of intraocular fluid, 
culture or other bacteriological examination of ocular fluids, Gupta et al 
proposed the following guidelines for the diagnosis of intraocular tuberculosis. 
“Taken broadly , these diagnostic criteria enable the clinician to determine 
when to initiate ATT. All the criteria are broadly described under five sections 
as described below. 
Section 1 Clinical signs 
All signs mentioned in table 2 page 16  
Section 2  Ocular investigation 
A. Demonstration of AFB by microscope or culture of  M.tuberculosis from 
the ocular fluids. 
B. Positive polymerase chain reaction from ocular fluids for IS 6110 or 
other conserved sequences in M.tuberculosis genome. 
 
 
 
 Section 3  systemic investigations    
1. positive mantoux test 
2. evidence of healed or active tubercular lesion on radiography of chest. 
3. evidence of confirmed active extrapulmonary tuberculosis either by 
microscopic examination or by culture of the affected tissue for 
M.tuberculosis 
section 4 exclusion of other Uveitis entities 
In the geographic regions where tuberculosis is low in incidence, other 
causes of Uveitis must be excluded by various laboratory investigations 
including serology for syphilis , toxoplasmosis and others. 
Section 5 therapeutic test  
A positive response to 4 drug ATT over a period of 4 to 6 weeks. 
Therapeutic trial with single drug isoniazid should be avoided due to risk of 
development of resistence. It is important to refer such a patient to a TB expert 
who can initiate and monitor the treatment. The therapeutic response to ATT in 
the eye should however be evaluated by the ophthalmologist. 
 
 
        Any one or more of the clinical signs listed under subsequent section 1 in 
combination with any of the positive tests under section 2 could be considered 
a confirmed case of intraocular tuberculosis. Any one or more of the clinical 
signs listed under section 3 or a positive therapeutic trial section 5 in 
combination with 4 could be considered presumed ocular tuberculosis and 
referred to a TB specialist to initiate a full course of ATT.”  
   
  
 
 
TREATMENT 
 Recommended therapy for tuberculosis Uveitis consists of  -  isoniazid  
5mg/kg/d, rifampicin 450 mg/d if body weight is <50 kg and 600 mg if the 
weight is greater than 50 kg, ethambutol 15 mg/kg , and pyrazinamide 25 to 30 
mg/kg/d initially for  2 months. Thereafter, rifampicin and isoniazid are used 
for at least another 4 to 7 months.12 oral prednisolone is added at a dose of 
1mg/kg/d until a clinical response is seen then a slow reduction is established. 5  
Abu El et al studied 51 patients with  presumed tuberculous Uveitis 
treated with ATT and systemic corticosteroids & reported that, “ all eyes 
showed resolution of inflammation without any recurrence after stopping 
antituberculous therapy and systemic corticosteroids. Previous studies reported 
a favorable response to antituberculous therapy when administered 
concomitantly with systemic corticosteroids in a patients with presumed 
tuberculosis Uveitis.5 The management of active retinal vasculitis requires the 
use of systemic corticosteroids and appropriate anti tuberculous therapy. New 
vessel formation associated with retinal vasculitis and capillary closure 
responds to panretinal photocoagulation. Early vitrectomy and adequate 
endolaser photocoagulation should be considered in eyes with nonresolving 
vitreous hemorrhage associated with active fibrovascular proliferation”. 
 
 
However no clinical trials exists on the efficacy of topical or systemic steroids 
in ocular tuberculosis .7 we will be treating with lower dose of steroids  than 
usual prescribed dose (1mg/kg body wt/day) based on our clinical experience, 
to see the reduced steroid related toxicity with similar therapeutic benefit            
(except for lesions near macula or optic disc, which will be treated with the 
usual prescribed dose i.e., 1mg/kg body wt/day).       
PHARMACOLOGY OF ETHAMBUTOL 
Ethambutol is selectively tuberculostatic and clinically as active as 
streptomycin. Fast multiplying bacilli are more susceptible as are many 
atypical mycobacteria. Added to the triple drug regimen of RHZ it has been 
found to hasten the rate of sputum conversion and to prevent development of 
resistance. 
The mechanism of action of Ethambutol is not fully understood, but it 
has been found to inhibit arabinosyl transferases involved in arabinogalactan 
synthesis and to interfere with mycolic acid incorporation in mycobacterial cell 
wall. 
Resistance to Ethambutol develops slowly; in many cases it is due to 
alteration in the drug target gene. No cross resistance with any other 
antitubercular drug. 
 
 
About ¾  of an oral of  Ethambutol is absorbed. It is distributed widely 
but penetrates meninges incompletely and is temporarily stored in RBCs. Less 
than ½ of Ethambutol is metabolized. It is excreted in urine by glomerular 
filtration and tubular secretion; plasma t1/2 is 4 hrs.caution is required in its 
use in patients with renal disease. 
The most important ocular side effect of ethambutol is toxic optic 
neuropathy. Ethambutol produces few other symptoms such as nausea,rashes, 
fever, neurological changes are infrequent. Hyperuricemia is due to 
interference with urate excretion. 
 
  
 
 
TOXIC OPTIC NEUROPATHY 
Toxic optic neuropathies can present as an acute or chronic damage that 
may result from an acute or sustained exposure to the noxious substance. 
Although these resemble closely the pattern of the involvement that may occur 
from a nutritional deficiency closely, in some cases, it can present with an 
acute onset disk edema with marked visual loss (as in case of methyl alcohol 
poisoning). 
The various agents that can cause toxic optic neuropathy are: 
 
 
 
 
 
 
 
 
 
 
 
Amiadarone                                                            Aspidium 
Arsenicals                                                              Ethambutol 
Carbon disulfide                                                    Ethylene Glycol 
Dinitrobenzene                                                      Hexachlorophene 
Disulfiram                                                              Iodoform 
Haloquinols                                                           Isoniazid 
Intetrix                                                                   Methanol 
Iodoquinol                                                            Penicillamine 
Lead                                                                      Plasmocid 
Pheniprazine                                                         Tobacco 
Quinine                                                                 Thallium 
 
 
The list is exhaustive but nevertheless incomplete, and many new drugs 
are likely to be reported causing toxic neuropathies over a period of time. 
However, it is difficult to establish a direct cause-and-affect relationship in 
most cases. At the same time, knowing the cause of toxic neuropathy is the 
cornerstone in the treatment of the condition and may have far reaching 
medical and legal implications. 
Discontinuation of the exposure is the cornerstone in the treatment of the 
condition and in conditions for which a specific treatment exists, an accurate 
etiological diagnosis is essential. 
                                         
PATHOPHYSIOLOGY 
                                      The etiology is multifactorial.  
C. Impairment of vascular supply or metabolism by toxins 
D. In patients who abuse tobacco and alcohol -  malnutrition is the principal 
cause of the visual loss.  
 
 
 
 
 
 
 
The specific deficiencies in vitamins proteins with 
sulfur- containing amino acids, or  combination of both 
 
 
Accumulation of formic acid 
 
 
Formic acid and cyanide disrupts ATP production 
 
 
                             Impairment of ATP- dependent axonal transport 
 
 
                                             Optic neuropathy  
  It has been hypothesized that the chelating properties of ethambutol 
contribute to its neurotoxicity, but this has yet to be proven. The mechanism of 
the neurotoxicity that occurs from the antiarrhythmic amiodarone remains 
unclear. Researchers believe that it may relate to a lipidosis that is induced by 
the drug.23 
 
 
 
APPROACH TO PATIENT WITH SUSPECTED TOXIC 
OPTIC NEUROPATHY 
1. Possibility of inflammatory lesions and malignancies by appropriate 
investigations, visual fields, visual evoked potentials and neuroimaging 
should be ruled out. It may be advisable to consider a neuroimaging, 
preferably MRI in all cases. 
2. Complete blood count with indices, standard blood chemistries, protein 
electrophoresis, and folate levels should be evaluated. 
3. If all the above findings are normal, an ERG may be considered to 
exclude cone-rod dystrophy, which can manifest with optic disk pallor 
and central scotomas. 
4. If ERG is normal, serological tests for Leber's hereditary optic 
neuropathy mutation and a 24-hour urine collection to rule out lead and 
thallium poisoning may be considered. 
5. If all these test are negative, or if there is a specific deficiency of 
nutrients as picked up by the blood tests, treatment with thiamine, 50 
mg/day, multivitamins, and possibly cyanocobalamin should be done. 
Patients should be encouraged to stop tobacco smoking and limit alcohol 
consumption. 
 
 
HISTORY: 
Should include : 
1. Diet history 
2. History of exposure to toxins/drug 
3. Personal history ( smoking/ drinking alcohol ) 
4. Occupational history (exposure to occupational toxins ) 
5. History of chronic disease or illness 
6. Family history 
 SIGNS AND SYMPTOMS:  
1. Bilateral painless progressive defective vision 
2. Decreased color vision 
3. Decreased contrast sensitivity 
4. Centrocaecal scotoma 
5. Optic disc pallor involving the temporal quadrant. 
6. No rapd 
7. Pupils : bilateral sluggish reaction to light 
8. Disc hyperemia and edema in few acute intoxications 
9. In ethambutol toxicity – fundus normal initially, later atrophy develops 
10. In isoniazid toxicity – optic disc swelling is seen 
 
 
11. In Amiodarone Toxicity – Bilateral Disc Swellimg With Flame Shaped 
Hemorrhage 
                              
Investigations 
Evaluation for toxic optic neuropathy includes a complete ocular 
examination including color vision, contrast sensitivity and visual fields.  
Visual field testing and color vision testing absolutely essential in the 
evaluation of any patient suspected of  having toxic optic neuropathy. Central 
or cecocentral scotomata with preservation of the peripheral field are 
characteristic visual field defects. These cases show red green colour defects, 
but sometimes blue yellow defects may also be seen. 
COLOR VISION : 
Colour sense is the ability of the eye to discriminate between colours 
excited by light of different wavelengths.  
THEORIES OF COLOR VISION 
Trichromatic theory—Young-Helmholtz (1802) proposed “ that color vision 
depends on the three different sets of retinal fibers responsible for perception of 
red, green, and violet”. 
Opponent theory—Hering (1878) proposed that  “yellow-blue and red-green 
represent opponent signals producing four color primaries red, green, yellow, 
 
 
and blue and not just three”. Whiteblack opponency proposed by him has been 
abandoned in most modern versions of the theory. 
Zone theory—Donder (1881) proposed that “ the Trichromatic theory operates 
at the receptor level and the Opponent theory applies to the subsequent neural 
level of color vision processing. This is the basis of modern color vision 
theory. At the receptor level vision is trichromatic (based on the perception of 
three primary colors) and requires three types of cone photopigment. Each 
photopigment absorbs particular wavelengths of light in the short (blue, 440 
nm), middle (green,545 nm), or long (red, 560 nm) wavelength region of the 
visible spectrum. These cones are the basic mediators of color vision. 
If one or more of their pigments is missing, color blindness results”. 24 
 
 
 
 
 
 
COLOUR VISION TESTS: 
Pseudoisochromatic Plate 
Ø Ishihara Plates 
Ø Standard Pseudoisochromatic Plates 
Ø Color Vision Testing Made Easy (CVTME) 
Ø City University test 
Ø American Optical Hardy-Rand-Rittler Plates 
Ishihara Charts 
This test is based on the principle of confusion of the pigment color in 
red-green color defectives. This is an easy and rapid test used most commonly 
for screening purposes. Ishihara charts are available in 14, 24 or 38 plates. The 
10th edition of Ishihara has 38 plates. Five different design formats are used in 
38 plates Ishihara.24 
Interpretation:  
The number of plates of each sub-type varies with the edition. For the 
38-plate edition, plates 1 to 21 are for screening red-green defects, and plates 
22 to 25 are for differential diagnosis of protans and deutans. The plates are 
designed to be appreciated correctly in a room which is lit adequately by 
daylight. The plates are held at a distance of 75 cm perpendicular to the line of 
sight. 
 
 
Out of 21 plates, if 17 or more plates are read correctly by an individual 
his color sense should be regarded as normal. If 13 or less plates are correctly 
read then the person has a red-green color defect.9 Disadvantage of this test is 
that it neither tests for tritanope 
nor grades the degree of deficiency. 
American Optical Hardy- Rand-Ritter (HRR) is the test of choice for 
quantitative diagnosis and the Standard Pseudoisochromatic Plates Part for 
acquired color deficiency.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISHIHARA PLATES 
 
 
 
 
 
 
HARDY – RAND- RITTLER : 
1. It is a pseudo isochromatic chart test. 
2. Useful to identify protan, deutran, tritan defects. 
3. Consists of 24 plates with vanishing designs containing geometric 
shapes. 4 plates are introducing plates, 6 are for screening, 10 are for 
grading severity of protan and deutran defect and last 4 for grading tritan 
defect. 
THE LANTERN TEST : 
The subject has to name various colours shown to him using lantern. 
There are three types: 
1. EDRIGE GREEN 
2. HOLMES WRIGHT TYPE A 
3. HOLMES WRIGHT TYPE B 
FARNSWORTH MUNSELL 100 HUE TEST : 
It is a spectrographic test where the colored chips are arranged in 
ascending order. 
CITY UNIVERSITY COLOR VISION TEST: 
It is also spectrographic test. 
Here, colored plates are matched to closest hue from 4 sorrounding color 
plates. 
 
 
NAGELS ANOMALOSCOPE TEST : 
The observer is asked to mix red and green color in a proportion to 
match the given yellow color hue.  
It detects red-green deficiency 
HOLMES’ WOOL TEST : 
The subject is asked to make a series of color matches from a selection 
of colored wools. 
CENTRAL FIELDS TESTING 
TANGENT SCREEN 
The tangent screen may be used at a distance of one or two meters, and 
should be able to test central 30o of  the patient’s visual fileds. 
An uniform illumination of 7 foot candles is preferred Visual fields 
could be tested kinetically by moving the stimulus from periphery towards 
fixation .visual fields can also be tested statically with test objects shown 
intermittently. 
Fixation can be tested repeatedly by concealing and exposing the test 
objects in the blind spot area. Fixation has obviously shifted , if the patient can 
see the object in the blind spot area. 
Thus, the Bjerrum screen can provide more detailed, quantitative visual 
field information than that afforded by confrontation visual field testing. It may 
 
 
even provide information that is equal to or better than those provided by the 
automated perimeters, in the hands of a skilled perimetrist. 21 
CONTRAST SENSITIVITY: 
Contrast sensitivity is the ability to perceive slight changes in luminance 
between regions that are not separated by definite borders and is just as 
important as the ability to perceive sharp outlines of relatively small objects. It 
is only the latter ability that is tested by means of the snellen’s test 
types.Further , contrast sensitivity may be impaired even in the presence of 
normal visual acuity.22 
TYPES OF CONTRAST SENSITIVITY: 
1. SPATIAL CONTRAST SENSITIVITY: 
Spatial contrast sensitivity refers to detection of striped pattern at various 
levels of contrast and spatial frequencies. In its measurement, patient is 
presented with sine wave gratings of parallel light and dark bands and is asked 
to tell the minimum contrast at which the bars can be seen at each frequency. 
The width of the bars is defined as spatial frequency which expresses the 
number of pairs of dark and light bars subtending an angle of 1 degree at the 
eye. A high spatial frequency implies narrow bars, whereas low spatial 
frequency indicate wide bars.22 
 
 
 
2. TEMPORAL CONTRAST SENSITIVITY: 
Here the contrast sensitivity function is generated for time related 
processing in the visual system by presenting a uniform target field modulated 
sinusoidal in time, rather than as a function of spatial position. 
Both temporal and  spatial contrast sensitivity testing yield significantly 
more complete and systematic data on the status of visual performance than the 
conventional tests. 
MEASUREMENT OF CONTRAST SENSITIVITY: 
When a subject is presented with the grating frequencies and contrast 
below which resolution is impossible, it indicates the threshold level; and the 
reciprocal of this contrast threshold gives the contrast sensitivity. 
Contrast sensitivity is measured as (Lmax – Lmin)/(Lmax+ Lmin), 
where L is the luminance recorded by photocells scanning across the gratings. 
METHODS OF MEASUREMENT: 
Various methods have been developed to measure contrast sensitivity. 
Boldis  wollner introducing contrast sensitivity measurement in clinical 
practice, suggested the name visugram , analogue to an audiogram , to describe 
a patient’s  ‘contrast sensitivity curve’. 
 
 
 
The deficits were expressed in terms of decibels , and three types of deficits 
were described: 
1. High –frequency type characterized by increasing loss at high frequency 
2. A level-loss type characterized by a similar loss for all spatial 
frequencies. 
3. A selective loss type characterized by deficits of spatial frequencies in a 
narrow band 
In general, the methods recommended to measure contrast sensitivity 
include: 
Simple plates, cathode ray tube display on a screen, letter acuity charts, 
laser interferometer which produces grating on retina, visual field testing 
using low contrast rings on stimuli , pattern discrimination test , proto 
type for forced choice printed test, visually evoked cortical potentials to 
checkerboard pattern reversal dependent contrast threshold measurement 
, two alternative forced choice test and many more. 22 
        Some of the simple, inexpensive but reliable methods of measuring 
contrast sensitivity are described in belief in the following text 
1. ARDEN GRATINGS: 
Arden in 1978 introduced a booklet containing seven plates: one screening 
plate and six diagnostic plates. 
 
 
The contrast changes from top to bottom and covers a range of 
approximately 1.76 log units. The plates are studied at 57 cm with spatial 
frequency increasing from 0.2 cycles /degree to 6.4 cycles/degree , each 
being double the frequency of the previous one. A score of 1-20 is assigned 
to each plate depending upon the amount of plate uncovered. Sum of six 
plates with an upper limit of 82 was established for normal subjects together 
with an intraocular difference of less than 12.22 
2. CAMBRIDGE LOW- CONTRAST GRATINGS: 
Cambridge low-contrast gratings consist of a set of ten plates containing 
gratings in a spiral bound booklet. To perform the test the booklet is hung 
on a wall at a distance of 6 m. the pages are presented in pairs, one above 
the other. 
One page in each pair contains gratings and the other is blank but the pages 
have the same mean reflectance. The subject is simply required to choose 
which page, top or bottom, contains the gratings. The pages are shown in 
order of descending contrast and are stopped when the first error is made. 
Depending upon the total score of a patient from four series, the contrast 
sensitivity is noted from the conversion table. 
 
 
 
 
3. PELLI – ROBSON CONTRAST SENSITVITY  CHART  
This chart consists of letters that subtend an angle of 3 degree at a distance of 
1m. The chart is printed on both sides. The two sides have different letter 
sequence but are otherwise identical. The letters on a chart are organized as 
triplets , there being two triplets in each line. The contrast decreases from one 
triplet to the next. The log contrast sensitivity varies from 0.00 to 2.25. 
To perform the test, the chart is hung on the wall, so that its centre is 
approximately at the level of the subject’s eye. The chart is illuminated as 
uniformly as possible, so that the luminance of the white areas is between the 
acceptable range 60 and 120 cd/m which corresponds to a photographic 
exposure between 1/15 and 1/30 second at f/5.6 with ASA of 100. The 
luminance is determined with the help of light meter. 
While recording, the subject sits directly in front of the chart at a distance of 
1m (with best distance correction). The subject is made to name or outline each 
letter on chart starting from the upper left corner and reading horizontally 
across the line. Subject is made to guess even when he or she believes that the 
letters are invisible. The test is concluded when the subject guesses two of the 
three letters of the triplet incorrectly. The subject’s sensitivity is indicated by 
the finest triplet for which two of the three letters are named correctly. 25 
 
 
 
 
 
4. VISTECH CHART  : 
This chart consists of sine wave gratings and is used at a distance of 3 m 
from the subject. In the test, contrast is assessed at several spatial frequencies 
and the subject has to identify orientation of grating, i.e., whether vertical or 15 
degree clockwise or anticlockwise.22 
 
 
 
 
 
FACTORS AFFECTING CONTRAST SENSITIVITY: 
1. REFRACTIVE ERRORS 
Visibility of low spatial frequencies is not limited by the refractive 
property of the eye; the refractive errors affect only the higher frequencies. 
2. AGE 
There occurs a definite decrease in contrast sensitivity with increasing 
age. It has been reported that from twenties onwards, contrast sensitivity scores 
for normal population decline with age by about 10% for each decade of life. 
3. LENTICULAR CHANGES 
Early lens changes can reduce contrast sensitivity essentially for low spatial 
frequencies. This decrease in contrast sensitivity is not related to the visual 
acuity. 
4.OCULAR AND SYSTEMIC ILLNESS 
Contrast sensitivity is also found to be affected by various ophthalmic as 
well as systemic diseases. It is decreased in cases with retinal , optic nerve and 
visual pathway diseases, glaucoma, ocular hypertension, retro bulbar neuritis, 
multiple sclerosis, amblyopia, diabetes mellitus, pituitary adenoma etc.,                                
 
 
 
 
 
MANAGEMENT:  
Stopping the offending agent is the first step in managing toxic optic 
neuropathy. This may cause some reversal of the process. Once the drug is 
stopped, recovery time varies from weeks to months. 
Recovery of vision after stopping ethambutol is still a question. Vision 
can either drop or remain the same or fail to recover.  
Isoniazid-caused toxic neuropathy can either be stabilized or reversed by 
giving  Pyroxidine 25-100mg/day.  
Follow up of patients with toxic optic neuropathy is initially done at 
every 4-6 weeks and then, depending on their recovery, every 6-12 months. At 
each visit, the following test are to be done : 
1. Visual acuity 
2. Pupils to be examined 
3. Color vision 
4. Contrast sensitivity 
5. .central fields 
6. Optic disc has to be examined.20 
 
 
 
 
 
PROGNOSIS: 
Recovery of vision usually happens over several days to weeks in toxic 
optic neuropathy, once the offending agent is removed.  
Prognosis  depends on 
1. offending agent  
2. Total amount of exposure. 
 Few  cases show minimal improvement, few no improvement.23 
 
  
 
 
ETHAMBUTOL-INDUCED OPTIC NEUROPATHY 
Ethambutol toxicity is frequently described as a dose and duration 
related optic neuritis that varies in incidence according to the dose of the drug 
used. The significance of recognizing this entity is that this condition is a 
potential cause of visual loss in patients undergoing anti-tubercular therapy and 
warrants a prompt alteration of therapy.23 
The condition usually develops in the patients taking Ethambutol in 
doses of 15 to 20 mg/kg/day for 3 to 6 months taken for pulmonary disease. 
However, it can present earlier or progress more rapidly in patients with renal 
disease. The condition has also been reported in patients taking standard doses 
for less duration. Although ethambutol optic neuropathy is thought to be both 
dose and duration related, there is no definite safe dosage. 
Presenting ocular features : 
1. Bilateral progressive painless defective vison 
2. Decreased color perception 
3. Vision drop 
4. Both eyes symmetrically involved- no RAPD 
5. Central scotoma 
6. Bitemporal field defects 
7. Peripheral constriction of fields 
 
 
8. Dyschromatopsia 
9. Fundus may remain normal until late stage or may show disc pallor 
According to the available reports from literature, testing for the central 
visual fields, visual evoked potentials and color vision are the most sensitive 
indicators but in the wake of the fact that the patient may be immobile, it may 
be difficult for the patient to undergo them.23  
Tests for color vision may be performed at the bedside. Ishihara's 
pseudoisochromatic charts may not be the ideal method of assessment as a 
descriptive study on color vision testing in 42 patients with systemic 
tuberculosis who received ethambutol, showed. It showed that 15 (36%) 
patients with high total error scores at the Farnsworth-Munsell 100 test had 
normal color vision measured by Ishihara pseudo-isochromatic plates. As 
mentioned above, the earliest field defects may not be actually red-green visual 
field defects but rather blue-yellow color vision abnormalities. 23 
TREATMENT : 
Treatment consists of a cessation of ethambutol. In case any of these 
above mentioned parameters show derangements, ethambutol should be 
stopped. Early cessation can help in the recovery of the patient. Many people 
also advocate stopping isoniazid simultaneously as both can cause optic 
neuropathy.26 
 
 
Administration of concomitant steroids has neither been proven to be 
useful nor is indicated keeping in view the possible promotion of the growth of 
the micro-organisms. Improvement in the visual acuity usually follows a 
cessation of ethambutol treatment. Rarely, vision continues to deteriorate or 
vision fails to recover after administration of the drug is stopped. However, 
contrary to the same, there are some reports which report that there is only a 
small improvement in visual acuity in such patients.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Ethambutol is a well-documented cause of optic neuropathy,  with dose-
related severity.25 Ethambutol toxicity has been more pronounced  in 
individuals with decreased zinc levels. Zinc dependant factors are known to 
preserve mitochondrial homeostatsis. One possibility for ethambutol toxicity is 
chelation of intracellular zinc.24 
Christopher et al stated that , “ Although EMB-induced optic neuropathy 
is often reversible, permanent damage may occur at standard doses (15–25 
mg/kg/day). Sustained periods of standard loading dose (25 mg/kg/day) have 
been shown to have a higher incidence of optic neuropathy than therapeutic 
levels (15 mg/kg/day). It is important to note that visual deficits can occur at 
any time from 2 to 12 months after initial treatment”. 26,27,28                            
Ethambutol has been found to be specifically toxic to retinal ganglion 
cells via an excitotoxic pathway for which endogenous glutamate plays a major 
role. Also John E Heng et al suggested “ glutamate antagonists may be useful 
in limiting the side effects of ethambutol”.30,31,32 
Eun Ji Lee et al studied “ incidence and clinical features of ethambutol-
induced optic neuropathy in korea”. They did a retrospective chart review of 
857 patients who took ethambutol for treatment of tuberculosis identified 89 
 
 
patients with ethambutol induced optic neuropathy. Ethambutol induced optic 
neuropathy was diagnosed in 1.5% patients in a follow up of 1 yr +/- 9 months. 
Based on their study , the incidence of ethambutol induced optic neuropathy in 
Koreans is estimated to be <2%. Reversibility  in visual function after stopping 
ethambutol is noted in minority of patients. They also found renal dysfunction 
and daily dose of ethambutol , but not duration of ethambutol treatment , seem 
to be related to development of  Ethambutol Induced Neuropathy. 33 
Hsin-Yi Chen et al did a nationwide population based study on 
ethambutol induced optic neuropathy. They studied the risk factors and 
comorbidities associated with ethambutol induced optic neuropathy. They 
reported “age, hypertension and renal diseases to be risk factors in Taiwanese 
population. They identified 231 patients newly diagnosed with EON between 
2000 and 2008”.34 
Edward G. DeVita et al studied optic neuropathy in Ethambutol – treated 
renal tuberculosis. They presented two cases of severe ,nonreversible optic 
neuropathies resulting from the treatment of renal TB with ethambutol at 
standard doses. They found that the patients with renal TB are at risk to 
develop bilateral severe and irreversible toxic optic neuropathies. They 
recommended that ethambutol is not to be used in treatment of  renal TB or in 
any patient with decreased renal function.35 
 
 
Hamzah mustak et al studied ethambutol induced  toxic neuropathy in 
HIV positive patients and found that HIV and, perhaps more importantly, the 
potential mitochondrial toxic effects of NRTIs may be a risk factor for the 
development of toxic optic neuropathy from ethambutol therapy via a multiple 
hit effect. They  recommended regular monitoring  for HIV positive patients 
receiving antiretrovirals and requiring ethambutol  therapy in order to avoid 
permanent visual loss.36 
Alex Melamud et al reported few cases of ocular ethambutol toxicity. 
Their review of literature revealed that “ethambutol toxicity occurs at the 
lowest recommended dosage levels and toxicity occurs despite regular 
monitoring and close medical and ophthalmologic follow up. They also found 
that ethambutol toxicity can cause severe vision loss that is often permanent 
and irreversible”.37 
Salmon J F et al studied use of contrast sensitivity in the detection of 
subclinical ethambutol toxic optic neuropathy and suggested that “Arden 
contrast sensitivity plates would be effective in detecting subclinical toxic optic 
neuropathy due to ethambutol and therefore could be used for routine 
monitoring of ocular function of patients on ethambutol”. 39 
 
 
 
Christopher et al studied use of optical coherence tomography in 
ethambutol induced neuropathy. They found that “ OCT showed loss of 
temporal fibers in patients with ethambutol induced optic neuropathy. They 
also found OCT can be a valuable tool in the quantitative analysis of optic 
neuropathies”. 39 
R S Behbehani  et al reported  “mERG abnormalities in the ethambutol 
treated patients. The N1 amplitude was significantly lower in the ethambutol 
treated patients than in the control group suggesting  Ethambutol is possibly 
toxic to the retina, and not only the optic nerve. The multifocal ERG may be of 
value to diagnose and monitor patients taking ethambutol”. 40 
Daniel Masvidal et al reported structural-function dissociation in 
presumed ethambutol optic neuropathy in a 55 yr old male with pulmonary 
mycobacterium infection. Medications were discontinued. Despite visual 
improvement after stopping ethambutol disc pallor and RNFL loss in OCT 
were progressive suggesting persistent structural changes.41  
  
                                            
 
 
 
 
 
TYPE OF STUDY:  Hospital based prospective study 
OBJECTIVES:    To evaluate the 
1. Incidence of Ethambutol induced optic neuritis 
2. Clinical characteristics of Ethambutol induced optic neuropathy. 
Risk factors & dosage information among patients who are treated with 
Ethambutol for tubercular Uveitis who are attending our Uvea clinic between  
November 2014 – April 2015 
Study Area: Aravind Eye Hospital and post graduate institute of 
ophthalmology, Madurai. 
Study period:  November 2014 to april  2015 
STUDY SUBJECTS: 
 Patients who were diagnosed with various forms of intraocular 
tuberculosis and was started on ethambutol between November 2014 to april 
2015 were enrolled for study. 
SAMPLE SIZE: 
60 patients who were diagnosed with intraocular Tuberculosis and 
started on Ethambutol from November 2014 to april 2015 (6 months ). 
 
 
 
 
PLAN OF WORK 
Patients with tubercular uveitis who are treated with ethambutol as part 
of  ATT regime attending our uvea clinic are being screened at first visit 
followed by 3months  after  first visit for ethambutol induced optic neuritis. 
INCLUSION CRITERIA: 
 All patients who presented to Uvea clinic of Aravind eye hospital  
between November 1st  2014 to 31st  April 2015 with “definitive clinical signs 
of intraocular inflammation” compatible with a diagnosis of ocular 
tuberculosis5  who were started on ethambutol were included in the study. In 
our study we followed the guidelines given by Gupta et al for  Diagnosis of 
Intraocular Tuberculosis. 
EXCLUSION CRITERIA: 
Ø Best corrected visual acuity <6/36 
Ø Addiction to alcohol/smoking/cannabis 
Ø Decreased vision due to media opacity like cataract and corneal opacity 
Ø Patients diagnosed with glaucoma at the time of initiation of Ethambutol 
Ø Patients diagnosed with optic neuropathy due to other causes like AION, 
NA-AION, hereditary optic neuropathy, multiple sclerosis. 
 
 
Ø Patients with congenital optic disc anomalies 
Ø Patients who are taking amiodarone, Immunosuppressive, anti cancer 
agents.  
 
 
   
  
 
 
CLINICAL EVALUATION 
A series of 60 patients who presented to our Uvea clinic who were 
diagnosed with intraocular Tuberculosis and started on Ethambutol were 
included in our study. All these patients underwent thorough ophthalmological 
examination.  
The patient’s particulars like name , age, sex, weight address were 
documented in a proforma specially designed for the study and was filled by 
the examining doctor. 
Detailed history of each and every symptom of the patient was taken 
such as onset , duration of defective vision, progression and associated factors 
like exposure to any other toxins were documented. 
The patients were also enquired about past medical , surgical history, 
systemic illness, treatment history, personal history and family history and the 
same was noted. 
EACH ONE OF THE PATIENT INCLUDED IN OUR STUDY HAD TO 
UNDERGO ROUTINE OPHTHALMIC EVALUATION. 
Ø Visual acuity was recorded with snellen’s visual acuity chart 
Ø Refraction was done 
Ø Pupillary reaction  for normal, sluggish or RAPD was noted 
 
 
Ø Anterior segment findings in both eyes were noted with slit lamp 
biomicroscopy 
Ø Fundus examination was done with 90D- slit lamp followed by indirect 
ophthalmoscopy 
Ø Type of tubercular Uveitis was determined following the previous tests. 
Ø Special attention was given to the appearance of optic disc 
Ø  Color vision was tested using pseudo -isochromatic ishihara color vision 
chart 
Ø Contrast sensitivity was tested using  pelli – robson contrast sensitivity chart 
Ø Central fields were tested using bjerrum screen 
Ø The above tests were repeated in follow up visit 
Ø Montoux test and  Systemic examination for primary focus of TB was done. 
Ø Radiological examination like chest x-ray, CT chest, CT abdomen was done 
to document other focus of TB whenever necessary. 
Ø PCR of ocular fluids to detect Tuberculosis bacilli were done whenever 
necessary. 
Ø Physician opinion was taken if there was any adverse reaction to drugs 
during follow up visit and  whenever necessary and the treatment was 
modified accordingly. 
 
 
Ø During follow up at 3 months after starting Ethambutol  visual acuity, 
refraction, color vision, contrast sensitivity, central fields, anterior and 
posterior segment evaluation with slit lamp biomicroscopy and indirect 
ophthalmoscopy was repeated. 
Ø Enquiry in to Adherence to treatment and any adverse reaction to drugs 
were done and physician opinion was taken if necessary.                                   
Ø The incidence of Ethambutol induced optic neuropathy and it’s clinical 
profile was analyzed.  
 
 
 
 
 
 
 
 
 
  The Mean (SD) of the age is 46.6(12.8) years & its range is 13 
Sex 
Male 
Female 
Total 
 
 
Female
43.3%
 
RESULTS 
AGE 
SEX 
n % 
34 56.7 
26 43.3 
60 100 
Male
56.7%
Sex
- 66 years 
 
 Eye 
Right Eye 
Left Eye 
Both Eye 
Total 
 
 
 
0
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60
Right Eye
11
 
EYE 
n % 
11 18.3 
7 11.7 
42 70.0 
60 100 
Left Eye Both Eye Total
7
42
 
60
 Laterality
Unilateral 
Bilateral 
Total 
 
 
0
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Unilateral
18
 
LATERALITY 
 n % 
18 70.0 
42 30.0 
60 100 
Bilateral Total
42
60
 
  The Mean (SD) of the 
ETHAMBUTOL DOSE
EthambutolDose 
15mg/kg 
20 mg/kg 
24 mg/kg 
Total 
 
 
0
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80
15 mg/kg
80.0
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rc
en
ta
ge
Ethambutol Dose
 
WEIGHT 
weight is 61.47(6.4) kg & its range is 45 
 
n % 
48 80.0 
11 18.3 
1 1.7 
60 100 
20 mg/kg 24 mg/kg
18.3
1.7
- 77 kg 
 
 Complaints 
Defective Vision 
Pain 
Redness 
Floaters 
Total 
 
 
 
60
 
COMPLAINTS 
n %
51 85.0
7 11.7
1 1.7
1 1.7
60 100
51
7
1
1
 
 
 
 
 
 
 
Defective Vision
Pain
Redness
Floaters
Total
 
 
TYPES OF UVEITIS 
Types of Uveitis n % 
Anterior 1 1.7 
Intermediate  10 17.0 
Posterior 46 76.7 
Pan Uveitis 4 6.7 
 
 
 
 
1
10
46
4
Anterior
Intermediate 
Posterior
Pan Uveitis
 
 
PAST HISTORY 
Past history n % 
Hypertension 3 5.0 
Diabetes 1 1.7 
Nil 57 95.0 
 
Parameters Visit1 Visit2 
Colour Vision 
    Normal 
    Missing 
(n=102) 
90(88.2) 
12(11.8) 
(n=102) 
100(98.0) 
2(2.0) 
Contrast Sensitivity 
    Normal 
    Missing 
(n=102) 
90(88.2) 
12(11.8) 
(n=102) 
98(96.0) 
4(4.0) 
Central Fields 
    Normal 
    Missing 
(n=102) 
90(88.2) 
12(11.8) 
(n=102) 
99(97.0) 
3(3.0) 
Background Retina 
Chorioretinits 
Chorioretinal scar 
    Choroidal granuloma 
    Multifocal choroiditis 
    Posterior scleritis 
Parsplanitis 
    Normal 
    Sclera abscess 
Vasculitis 
Choroiditis 
(n=102) 
14(13.7) 
27(26.5) 
19(18.6) 
5(4.9) 
3(2.9) 
14(13.7) 
- 
1(1.0) 
9(8.8) 
10(9.8) 
(n=102) 
4(3.9) 
60(58.8) 
6(5.9) 
3(2.9) 
3(2.9) 
12(11.8) 
3(2.9) 
- 
4(3.9) 
7(6.9) 
 Optic Nerve Head 
 Normal 
    Pallor 
    Edema 
Hyperemia 
Focus of TB 
Lymph node 
    Lung 
    Abdomen  
    Spine 
OCT 
   Yes 
   No 
 
 
0
10
20
30
40
50
60
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13.7
26.5
18.6
4.9
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13.7
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(n=102) 
99(97.0) 
1(1.0) 
1(1.0) 
1(1.0) 
(n=102) 
99(97.0) 
1(1.0) 
1(1.0) 
1(1.0) 
(n=60) 
8(13.3) 
40(66.7) 
12(20.0) 
- 
 
 
- 
 
- 
(n=60) 
- 
60(100) 
3 Months
3.9
58.8
5.9
2.9
2.9
11.8
2.9
0
3.9
9.8
6.9
Background Retina
Chorioretinits
Chorioretinal scar
Choroidal granuloma
Multifocal choroiditis
Posterior scleritis
Parsplanitis
Normal
Sclera abscess
Vasculitis
Choroiditis
 
 Visual 
Acuity 
n 
Median
(Snellen’s 
Equivalent)
Visit1 
Visit2  
102 
102 
0.78(6/36)
0.60(6/24)
*Paired t-Test 
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VISUAL ACUITY 
 
 
Mean(SD) Range 
 
 
0.68(0.26) 
0.56(0.21) 
6/6 - 1/60 
6/6 - 6/60 
<0.0001
3months
40.2
79.4
59.8
Visual Acuity
>= 6/18 < 6/18
P - 
value* 
 
 
 
 
DISCUSSION 
In our study we studied 60 patients who were diagnosed with various 
forms of intraocular tuberculosis who were given ethambutol for 2 months in a 
dose range of 15-24mg/kg. There was nil incidence of ethambutol induced 
optic neuropathy among our patients. The Mean age of the patients included in 
our study was 46.6 years and the SD was 12.8 years. The mean dose of 
ethambutol was 16 mg/kg/day. The mean duration of ethambutol in our study 
was 2 months.    
In general ethambutol induced optic neuropathy is considered to be both 
dose and duration related. Eun ji lee et al studied the incidence and clinical 
features of ethambutol induced optic neuropathy by doing a retrospective chart 
review of 857 patients. They found ethambutol induced optic neuropathy was 
found in 13 patients during follow up period of 12 +/- 9 months. In our study 
we followed up the patient until 3 months after starting on ethambutol since the 
incidence of ethambutol induced optic neuropathy was high at 3 months of 
starting theraphy. 
The average dose of ethambutol used in the study conducted by eun Ji 
Lee was 17+/- 2.21 mg/kg/day, and the duration of therapy was 9.38 +/10 
months. They reported a incidence of <2% in Koreans. 
 
 
In our study the average dose used was 16 mg/kg and the duration of 
therapy was 2 months. Less duration of therapy might explain the nil incidence 
of ethambutol induced optic neuropathy in our study. Also the study  
conducted by Eun Ji Lee et al had longer follow up record and larger sample 
size. 
However Carr RE  et al and Karmon G et al reported that ethambutol 
induced optic neuropathy develops from 15 days to 2 yrs after initiation of 
ethambutol treatment. The mean interval between starting medication and 
documentation of ethambutol induced optic neuropathy was found to be 3.4 
months to 5 months. But in the study conducted by Eun Ji Lee et al found the 
visual symptoms to have developed at 7.3 months +/- 9.45 months after 
treatment.  In our study most patients received dose of 15 mg/kg/day for 
2months. Few patients received 20mg/kg for 2 months. 
Citron et al and leiboid et al found that the estimated risk of ethambutol 
induced ocular toxicity falls below 1% when standard dose of 15mg/kg is used 
which coincides with results in our study since in our study we used standard 
dose of 15mg/kg/day for 2 months duration42. 
In our study we didn’t have patients with renal dysfunction. 
  De Vita EG et al  reported that impaired renal function was related to 
ethambutol induced optic neuropathy. Some investigators believe that patients 
 
 
with renal dysfunction have inappropriate drug levels and hence at higher risk 
of developing ethambutol induced optic neuropathy.                             
In our study none of the patients with hypertension  developed optic 
neuropathy. Hsin-Yi Chen et al  did a nationwide population – based study 
and investigated risk factors  and comorbidities  associated with ethambutol  
induced optic neuropathy. They found hypertension to be a risk factor for 
development of ethambutol optic neuropathy . 
In our study the patients were given ethambutol for 2 months duration. 
In the study by  Hsin-Yi Chen et al , they found that patients who were 
prescribed ethambutol more than 3 months were found to be at a mild elevated 
risk of ethambutol induced optic neuropathy when compared to patients who 
were prescribed ethambutol for less than 3 months(OR = 1.38, 95% CI 1.02 to 
1.86).                                      
 
 
 
 
 
 
  
 
 
CONCLUSION 
In our study, Standard dose of  Ethambutol  given for  duration  of  2 
months is found to be safe.  In our study, patients were given standard dose of  
Ethambutol for 2 months as part of treatment of  Tubercular Uveitis and  we 
found that there  was no incidence of Ethambutol Optic Neuropathy.  
  
 
 
LIMITATIONS 
1. Shorter follow up period. 
2. Small sample size. 
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PROFORMA 
Name:                                                                       MR NO: 
Age:                                                                           case no: 
Sex:  Male/female       male :1;   female:2                                            
weight : 
residential address:                                                  
duration of ATT:  
type of uveitis: 
anterior/intermediate/posterior/pan Uveitis      
anterior:1 
intermediate:2       
posterior :3         
pan Uveitis:4        
   
ethambutol dose : ______/kg  
complaints:    
 defective vision:1      ; pain:       2;redness:     3;combined: 4;floaters:  5 
1.defective vision: 
Duration 
sudden/insidious 
painless/painful 
altered/decreased colour vision:  y/n 
 
 
history suggestive of field defects: y/n 
past history: 
systemic hypertension  :1 
renal disease :2 
diabetes:3 
glaucoma:4 
nil : 5 
personal history: 
h/o alcohol : y/n  if yes:1 
h/o smoking : y/n if yes:2 
nil : 3 
treatment history: 
h/o intake of other medications: 
if yes :1 
if no :2 
                       
ocular examination:                        re                                  le 
bcva: 
anterior segment: 
pupil: 
normal/sluggish/RAPD 
colour vision: 
 
 
normal :1 
abnormal :2 
central fields: 
normal:1 
abnormal:2 
contrast sensitivity: 
normal:1 
abnormal:2 
fundus: 
media: clear/haze 
optic nerve head: 
normal looking/pallor/edema/others 
normal:1 
pallor:2 
edema:3 
hyperemia:4 
macula: 
foveal reflex: present/dull 
background retina: 
chorioretinits:1 
chorioretinal scar:2 
choroidal granuloma:3 
 
 
multifocal choroiditis:4 
posterior scleritis :5 
parsplanitis : 6 
normal :7 
sclera abscess:8 
vasculitis :9 
choroiditis: 10 
others: 
investigations: 
focus of TB: lymph node :1; lung:2; abdomen :3; spine :4 
 
sd-oct: report if done for the case 
yes :1 
no :2 
 
 
                           
 
 
 
 
 
 
 
ABBREVIATION 
 
 WHO  - World Health Organization  
 ART  - Anti Retroviral Therapy 
 ATT  - Anti Tubercular Therapy 
 PCR  - Polymerase Chain Reaction 
 HIV  - Human Immunodeficiency Virus 
 AIDS  - Acquired Immunodeficiency Syndrome 
 CME  - Cystoid Macular Edema 
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1 akash sunil 3889018 13 2   nov-14 52 kg 2 months 15 mg/kg 1 2 5 3 2   4/60   6/6 1 1 1 1 1 1 6 7 1 1 2   feb-15   6/18    6/6 1 1 1 1 1 1 6 7 1 1 2
2 sankari 3894414 35 2     nov-14 60 KG 2 months 15mg/kg 1 3 5 3 2    5/60    6/36 1 1 1 1 2 1 2 2   feb-15    6/36   6/6 1 1 1 1 2 1 2 2
3 rahima 3862286 45 2     nov-14 65 kg 2 months 24 mg/kg 1 4 1 3 2    6/60    6/18 1 1 1 2 2 4 1 2   feb-15    6/60    6/18 1 1 1 2 2 4 1 2
4 beeran koya 3832493 47 1     nov-14 66 kg 2months 15 mg/kg 5 4 1 3 2    6/6   6/6 1 1 1 1 1 1 1 1 1 3 1   feb-15    6/6    6/6 1 1 1 1 1 1 2 1 1 3 2
5 rajeswari 3772341 66 2     nov-14 45 kg 2 months 15 mg/kg 3 4 5 3 2    6/24   6/6 1 1 1 1 1 1 7 1 1 2   feb-15    6/18    6/6 1 1 1 1 1 1 1 7 1 1 2
6 sivasudharsan 3877392 18 1     nov-14 45 kg 2 months 15 mg/kg 1 4 5 3 2    6/6   6/18 1 1 1 1 1 1 7 1 1 1 2   feb-15   6/6   6/18 1 1 1 1 1 1 7 1 1 1 2
7 soundarapandian 3880219 64 1     nov-14 77kg 2 months 15 mg/kg 1 3 1,3 3 2    6/18    6/6 1 1 1 1 1 1 4 7 1 1 2   feb-15    6/18    6/6 1 1 1 1 1 1 4 7 1 1 2
8 chinnasamy 3659885 23 1     nov-14 60 kg 2 months 15 mg/kg 1 3 5 3 2      6/36     1/60 1 1 1 2 3 1 1 2   feb-15     6/24      6/12 1 1 1 1 1 1 2 2 1 1 2
9 nupur chandra 3908664 29 2     nov-14 55 kg 2months 15 mg/kg 1 3 5 3 2      6/12     6/24 1 1 1 1 1 1 1 1 1 1 3   feb-15     6/12      6/12 1 1 1 1 1 1 2 2 1 1 2
10 naveen c 3865455 27 1     nov-14 60 kg 2 months 15 mg/kg 1 3 5 3 2     6/9     6/12 1 1 1 1 1 1 2 1 1 1 2   feb-15     6/9     6/9 1 1 1 1 1 1 2 2 1 1 2
11 murugan p 3797208 63 1     nov-14 65 kg 2months 15 mg/kg 1 3 5 3 2     6/12    6/36 1 1 1 1 1 1 2 1 1 1 3   feb-15     6/12    6/12 1 1 1 1 1 1 2 2 1 1 2
12 sarasu m 3466992 45 2   dec-14 65 kg 2 months 15 mg/kg 2 3 5 3 2     6/12    6/24 1 1 1 1 1 1 7 8 1 1 2   mar-15    6/12    6/12 1 1 1 1 1 1 7 7 1 1 2
13 azis kumar k 3496683 30 1   dec-14 70 kg 2 months 15 mg/kg 1 3 5 3 2     6/9   6/12 1 1 1 1 1 1 7 9 1 1 2   mar-15     6/9    6/9 1 1 1 1 1 1 7 9 1 1 2
14 krishnan a 3489883 45 1   dec-14 60 kg 2months 15 mg/kg 1 1 ,2 5 3 2     6/9    6/9 1 1 1 1 1 1 6 6 1 1 3   mar-15     6/9    6/9 1 1 1 1 1 1 7 7 1 1 2
15 sampath s 3914363 56 1   dec-14 75 kg 2months 15 mg/kg 1 3 5 3 2     6/36    6/24 1 1 1 1 1 1 10 10 1 1 2   mar-15     6/24    6/24 1 1 1 1 1 1 2 2 1 1 2
16 jayaprada 3896610 57 2   dec-14 65 kg 2months 15 mg/kg 1 2 5 3 2     6/24    6/24 1 1 1 1 1 1 6 6 1 1 2   mar-15     6/12    6/12 1 1 1 1 1 1 6 6 1 1 2
17 pushpa 3713226 52 2   dec-14 65 kg 2months 15 mg/kg 1 3 5 3 2      6/36    6/60 1 1 1 10 10 1 1 2   mar-15     6/36    6/36 1 1 1 1 1 1 10 10 1 1 2
18 saraswathi 3767194 55 2   dec-14 60 kg 2months 15 mg/kg 1 3 5 3 2      6/24   6/24 1 1 1 1 1 1 3 3 1 1 2   mar-15     6/24    6/24 1 1 1 1 1 1 2 2 1 1 2
19 karuppusamy m 3847545 55 1   dec-14 72 kg 2months 15 mg/kg 1 3 5 3 2     6/9    6/9 1 1 1 1 1 1 9 9 1 1 3   mar-15     6/9     6/9 1 1 1 1 1 1 9 9 1 1 2
20 ummal basiriya 3867539 49 1   dec-14 64 kg 2months 20mg/kg 1 2 5 3 2     6/60   6/36 1 1 1 6 6 1 1 2   mar-15    6/36    6/36 1 1 1 1 1 1 6 6 1 1 2
21 jaburuth nisha 3875966 47 2   dec-14 55 kg 2months 20mg/kg 1 2 5 3 2     6/12    6/60 1 1 1 10 10 1 1 2   mar-15    6/12   6/36 1 1 1 1 1 1 10 10 1 1 2
22 thennarasu 3479619 46 1   dec-14 65 kg 2months 15mg/kg 1 2 5 3 2     6/18    6/36 1 1 1 1 1 1 6 6 1 1 3    mar-15    6/18    6/36 1 1 1 1 1 1 6 6 1 1 2
23 sirajun 3772107 23 1   jan-15 55 kg 2months 15mg/kg 1 3 5 3 2     6/36    6/36 1 1 1 1 1 1 2 1 1 1 3   apr-15    6/18    6/18 1 1 1 1 1 1 2 2 1 1 2
24 nagarajan 3948544 35 1    jan -15 60 Kg 2months 20mg/kg 1 3 5 3 2     6/24    6/24 1 1 1 1 1 1 6 6 1 1 3   apr-15   6/18    6/18 1 1 1 1 1 1 6 6 1 1 2
25 anandhi 3954241 50 2   jan-15 55 kg 2months 15mg/kg 2 3 5 3 2     6/36    6/36 1 1 1 1 1 1 9 9 1 1 3   apr-15    6/18    6/18 1 1 1 1 1 1 2 2 1 1 2
26 papathi 3950140 55 2   jan-15 65 kg 2months 15mg/kg 1 3 5 3 2     6/60    6/36 1 1 1 10 2 1 1 3   apr-15   6/60    6/36 1 1 1 1 1 1 2 2 1 1 2
27 ansabraham 3953234 45 1    jan -15 70kg 2months 20mg/kg 2 3 5 3 2    6/36    6/36 1 1 1 1 1 1 3 2 1 1 3   apr-15    6/24   6/36 1 1 1 1 1 1 2 2 1 1 2
28 ravichandran 3954667 65 1   jan-15 65kg 2months 15mg/kg 1 2 5 3 2    6/60    6/36 1 1 1 4 7 1 1 2   apr-15   6/36    6/36 1 1 1 1 1 1 2 7 1 1 2
29 jesudas 3956640 55 1   feb-15 75 kg 2months 15mg/kg 1 3 5 3 2    6/36   6/36 1 1 1 1 1 1 9 9 1 1 2   may-15   6/36   6/36 1 1 1 1 1 1 2 2 1 1 2
30 amsath begum 3826142 35 2  feb 15 60 kg 2months 15mg/kg 1 3 5 3 2   6/36   6/24 1 1 1 1 1 1 10 2 1 1 2   may-15   6/36   6/24 1 1 1 1 1 1 10 2 1 1 2
31 suresh 3901970 45 1  feb 15 64 kg 2months 15mg/kg 2 3 5 3 2    6/9   6/24 1 1 1 1 1 1 7 5 1 1 2   may-15    6/9    6/18 1 1 1 1 1 1 7 5 1 1 2
32 yasoda 3466925 54 2  feb 15 57 kg 2months 20mg/kg 2 3 5 3 2   6/24   6/9 1 1 1 1 1 1 5 7 1 1 2   may-15   6/18   6/9 1 1 1 1 1 1 5 7 1 1 2
33 selvi 3664785 36 2  feb 15 62kg 2months 15mg/kg 1 3 5 3 2   6/36   6/9 1 1 1 1 1 1 4 7 1 1 3   may-15   6/36   6/9 1 1 1 1 1 1 4 7 1 1 2
34 anbujothy 3972421 42 2  feb 15 64 kg 2months 15mg/kg 1 3 5 3 2    6/24   6/24 1 1 1 1 1 1 3 2 1 1 2   may-15   6/24   6/24 1 1 1 1 1 1 3 2 1 1 2
35 shalini p 3041593 54 2  feb 15 70kg 2months 15mg/kg 1 3 5 3 2    6/9    6/36 1 1 1 1 1 1 7 3 1 1 3   may-15   6/9   6/36 1 1 1 1 1 1 7 3 1 1 2
36 mali.s.k 3968311 62 1  feb 15 65kg 2months 15mg/kg 1 3 5 3 2   6/36   6/36 1 1 1 1 1 1 2 4 1 1 2   may-15   6/36   6/36 1 1 1 1 1 1 2 4 1 1 2
37 lakshmi 3462800 64 2  feb 15 54kg 2months 15mg/kg 1 3 5 3 2   6/18   6/24 1 1 1 1 1 1 2 3 1 1 2   may-15    6/18   6/18 1 1 1 1 1 1 2 2 1 1 2
38 nagaraj 3962956 62 1  feb 15 60kg 2months 20mg/kg 1 3 5 3 2    6/24    6/24 1 1 1 1 1 1 3 3 1 1 2   may-15    6/24    6/24 1 1 1 1 1 1 3 3 1 1 2
39 mahadevi 3739989 60 2  feb 15 65kg 2months 15mg/kg 2 3 5 3 2    6/36   6/36 1 1 1 1 1 1 9 2 1 1 2   may-15    6/36   6/36 1 1 1 1 1 1 9 2 1 1 2
40 maheswaran 3565302 27 1  feb 15 55kg 2months 20mg/kg 1 3 5 3 2  6/24  6/36 1 1 1 1 1 1 3 3 1 1 2   may-15   6/24   6/24 1 1 1 1 1 1 2 2 1 1 2
41 uma 3777466 35 2  feb 15 60kg 2months 15mg/kg 1 2 5 3 2   6/36   6/60 1 1 1 2 6 1 1 1   may-15   6/36   6/24 1 1 1 1 1 1 2 6 1 1 2
42 audiammal 3593317 60 2  feb 15 55kg 2months 20mg/kg 1 3 5 3 2    6/36   6/36 1 1 1 1 1 1 3 2 1 1 2   may-15   6/36    6/36 1 1 1 1 1 1 2 2 1 1 2
43 lalam pullaiah 3978798 60 1   mar-15 54kg 2months 15mg/kg 1 3 5 3 2   6/24    6/36 1 1 1 1 1 1 2 1 1 1 2   jun-15    6/24   6/36 1 1 1 1 1 1 2 2 1 1 2
44 raji c 3979059 55 2   mar-15 65 kg 2months 15mg/kg 1 3 5 3 2   6/36    6/9 1 1 1 1 1 1 3 7 1 1 2   jun-15   6/24   6/9 1 1 1 1 1 1 3 7 1 1 2
45 pandiarajan 3975551 45 1   mar-15 64 kg 2months 15mg/kg 1 3 5 3 2    6/18    6/36 1 1 1 1 1 1 2 4 1 1 2   jun-15   6/18   6/36 1 1 1 1 1 1 2 2 1 1 2
46 radha krishnan 2670208 57 1   mar-15 58kg 2months 15mg/kg 1 3 5 3 2    6/36    6/24 1 1 1 1 1 1 3 2 1 1 2   jun-15   6/24   6/24 1 1 1 1 1 1 2 2 1 1 2
MASTER CHART
47 suresh 2645794 45 1   mar-15 55kg 2months 20mg/kg 1 3 5 3 2   6/24   6/18 1 1 1 1 1 1 10 2 1 1 2   jun-15   6/24   6/18 1 1 1 1 1 1 10 2 1 1 2
48 yusef sheik 3981088 56 1   mar-15 65kg 2months 15mg/kg 1 3 5 3 2    6/36  6/24 1 1 1 1 1 1 3 2 1 1 1   jun-15   6/24   6/24 1 1 1 1 1 1 2 2 1 1 2
49 noorun nasreema 3962342 55 2   mar-15 65kg 2months 15mg/kg 1 3 5 3 2    6/36   5/60 1 1 1 2 1 1 1 2   jun-15   6/36   6/36 1 1 1 2 2 1 1 2
50 ramasamy 3280161 45 1   mar-15 60kg 2months 15mg/kg 1 3 5 3 2    6/36   6/9 1 1 1 1 1 1 3 7 1 1 2   jun-15   6/24   6/9 1 1 1 1 1 1 2 7 1 1 2
51 mahadevi 3739989 35 2   mar-15 58 kg 2months 15mg/kg 1 2 5 3 2    6/36   6/6 1 1 1 1 1 1 6 7 1 1 2   jun-15   6/24   6/6 1 1 1 1 1 1 6 7 1 1 2
52 munevarrah 3400618 60 1   mar-15 60kg 2months 15mg/kg 1 3 5 3 2    6/6  6/36 1 1 1 1 1 1 7 3 1 1 1   jun-15   6/6   6/24 1 1 1 1 1 1 7 3 1 1 2
53 prabhu 3358130 55 1   apr-15 55kg 2months 15mg/kg 1 3 5 3 2    5/60   6/24 1 1 1 9 2 1 1 2   jul-15   6/36   6/24 1 1 1 1 1 1 2 2 1 1 2
54 selvam 3474085 57 1   apr-15 65kg 2months 15mg/kg 2 3 5 3 2   6/6  6/24 1 1 1 1 1 1 7 5 1 1 1   jul-15   6/6   6/18 1 1 1 1 1 1 7 5 1 1 2
55 mariammal 3968875 45 2   apr-15 67kg 2months 15mg/kg 1 3 5 3 2   6/18   6/36 1 1 1 1 1 1 2 3 1 1 1   jul-15   6/18   6/18 1 1 1 1 1 1 2 2 1 1 2
56 balasubramani 3472470 35 1   apr-15 55kg 2months 20mg/kg 1 3 5 3 2    6/36   6/9 1 1 1 1 1 1 1 7 1 1 1   jul-15   6/24   6/9 1 1 1 1 1 1 2 7 1 1 2
57 vijayaraja 3989134 45 1   apr-15 60kg 2months 15mg/kg 1 3 5 3 2    6/24   6/24 1 1 1 1 1 1 3 2 1 1 1   jul-15   6/24   6/24 1 1 1 1 1 1 2 2 1 1 2
58 krishnamoorthy 3904707 40 1   apr-15 65kg 2months 15mg/kg 1 3 5 3 2    6/60   6/36 1 1 1 1 2 1 1 2   jul-15   6/36   6/36 1 1 1 1 1 1 2 2 1 1 2
59 anuradha 3019903 45 2   apr-15 55kg 2months 20mg/kg 1 2 5 3 2   6/18   6/9 1 1 1 1 1 1 6 7 1 1 2   jul-15   6/18   6/9 1 1 1 1 1 1 6 7 1 1 2
60 mathan 3846722 30 1   apr-15 60kg 2months 15mg/kg 1 3 5 3 2   6/24   6/36 1 1 1 1 1 1 2 10 1 1 2   jul-15   6/24   6/24 1 1 1 1 1 1 2 10 1 1 2
